Parsaclisib

CAS No. 1426698-88-5

Parsaclisib( INCB050465 )

Catalog No. M23581 CAS No. 1426698-88-5

Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 290 In Stock
10MG 470 In Stock
25MG 763 In Stock
50MG 1053 In Stock
100MG 1422 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Parsaclisib
  • Note
    Research use only, not for human use.
  • Brief Description
    Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
  • Description
    Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP).
  • In Vitro
    Parsaclisib (0.1-3000 nM; 4 d) inhibits proliferation of MCL and DLBCL cell lines.Parsaclisib (0.1-1000 nM; 2 h) inhibits anti-IgM-induced pAKT (Ser473) in the Ramos Burkitt’s lymphoma cell line, with an IC50 of 1 nM.Parsaclisib inhibits the proliferation of human, dog, rat, and mouse primary B cells after activation of these receptors, with IC50s ranging from 0.2 to 1.7 nM. Cell Proliferation Assay Cell Line:Jeko-1, Mino, JVM2, Rec-1, Pfeiffer, SU-DHL-5, SU-DHL-6, WSU-NHL, SU-DHL-4, SU-DHL-8, and WILL-2 cells Concentration:0.1-3000 nM Incubation Time:4 days Result:Resulted in a maximal inhibition of 70-90%, with IC50s of ≤10 nM in the four MCL cell lines.Pfeiffer, SU-DHL-5, SU-DHL-6, and WSU-NHL were highly sensitive, with IC50s from 2 to 8 nM.
  • In Vivo
    Parsaclisib (10 mg/kg; oral gavage twice daily for 7-19 days) inhibits tumor growth in the BALB/c mice bearing the A20 murine lymphoma cells.Parsaclisib (0.1-10 mg/kg; p.o. twice daily) slows Pfeiffer xenograft tumor growth in a dose-dependent manner. And Parsaclisib was well tolerated.Parsaclisib (0.5-1 mg/kg; a single p.o.) inhibits pAKT (Ser473) in Pfeiffer subcutaneous mouse xenograft models. Animal Model:Female BALB/c mice (5-9 weeks) were inoculated with A20 cells Dosage:10 mg/kg Administration:Oral gavage twice daily for 7-19 days Result:Resulted in significant tumor growth inhibition (TGI).Reduced the percentage of Tregs (CD4+CD25+FOXP3+) in tumors and spleens.Increased the ratio of CD4+ and CD8+ T cells to Tregs in spleens and tumors.Decreased the number of CD4+CD44high and CD8+CD44high T cells in both spleens and tumors.
  • Synonyms
    INCB050465
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    PI3K
  • Recptor
    PI3Kδ
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1426698-88-5
  • Formula Weight
    432.88
  • Molecular Formula
    C20H22ClFN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:122 mg/mL?(281.83 mM;?Need ultrasonic)
  • SMILES
    CCOc(c([C@H](C)n1nc(C)c2c(N)ncnc12)c1)c([C@@H](C2)CNC2=O)c(F)c1Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Niu Shin, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Research. 2015, Aug. 75(15).
molnova catalog
related products
  • PI3K inhibitor X

    PI3K inhibitor X (XL-147 analog) is a derivative of XL147 that acts as a reversible inhibitor.

  • PIK-108

    PIK-108 is an allosteric inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunits β and δ (PI3Kβ/δ).

  • LX-2343

    LX-2343 is an non-ATP competitive PI3K inhibitor that negatively regulates AKT/mTOR signaling.